( R )-(+)-2-Amino-2‘-hydroxy-1,1‘-binaphthyl (NOBIN, 5 ) can be readily converted into a series of novel N,N -disubstituted aminophosphines 9 and 23 − 25 . The N,N -dimethyl derivative ( R )- 9 (MAP) was prepared via a sequence involving reductive alkylation with CH 2 O and NaBH 4 ( 5 → 6 ), Pd(0)-catalyzed coupling of the corresponding triflate with Ph 2 P(O)H ( 7 → 8 ), and reduction of the resulting phosphine oxide with Cl 3 SiH ( 8 → 9 ). Variation of this scheme was required for the preparation of 23 − 25 as the phosphinylation failed in the presence of bulky N substituents; the N -protected triflate 17 was first coupled with Ph 2 P(O)H, and the resulting phosphine oxide 18 was reduced with Cl 3 SiH to give the aminophosphine 19, which was then subjected to reductive alkylation with individual ketones and NaBH 4 . The new P,N -binaphthyls thus obtained ( 23 − 25 and 9 ) were utilized as chiral ligands in Pd(0)-catalyzed allylic substitution. The enantioselectivites obtained for racemic 1,3-diphenylprop-2-en-1-yl acetate (±)- 26 and malonate nucleophiles, which gave ( S )-(−)- 28, ( R )-(+)- 29, and ( R )-(+)- 30 as the respective products (in up to 71−73% ee at room temperature with Cs 2 CO 3 in CH 2 Cl 2 and 9 or 23 as a ligand), are interpreted in terms of the chelated transition state 37 and preferential attack at the allylic terminus that is trans with respect to the phosphorus acceptor atom.
No takes yet. Share an insight, caveat, or question.
Vyskočil et al. (1998) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: